A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Phase 2
220
about 2.4 years
18–74
16 sites in CA, FL, IL +8
What this study is about
Researchers are testing a treatment called IMG-007 compared to a placebo for adults with moderate-to-severe atopic dermatitis. The trial will last 866 days, and the goal is to enroll 220 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take IMG-007
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Mean percent change from baseline in EASI at Week 20
Secondary: Incidence and severity of TEAE including treatment-emergent SAEs, Mean percent change from baseline in EASI at Week 16
Dermatology